This study aims to explore how certain health and wellness products can affect fatigue and other related health outcomes in adults living in the United States. It is designed to see if these products can offer a meaningful improvement of at least 30% in the participants' primary health concerns. The study is important as it could provide insights into effective ways to manage fatigue, which is a common problem impacting many people's daily lives. To ensure accurate results, participants must agree to take a product, not knowing whether they are receiving an actual wellness product or a placebo until the study concludes. Participants in the study will provide self-reported health data electronically over a period of seven weeks, without needing to attend any in-person visits. Health indicators are assessed at the beginning and throughout the study, with a final survey at the end. The study is carefully designed to ensure safety, excluding individuals with certain health conditions, heavy drinkers, and those who are pregnant or breastfeeding. By collecting data electronically, the study aims to reflect real-world conditions and gather valuable evidence on the effectiveness of these wellness products in reducing fatigue.
Inclusion Criteria: * Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed * Resides in the United States * Has the opportunity for at least 30% improvement in their primary health outcome * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study Exclusion Criteria: * Report being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address and mobile phone number * Reports current enrollment in another clinical trial * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. --NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. --Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products * Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk * Lack of reliable daily access to the internet
are designated in this study
of being blinded to the placebo group